Combined detection of the exosomal membrane proteins EGFR and HER2 improves the diagnostic sensitivity of pancreatic cancer (85%) and is particularly effective in CA19-9-negative patients (88). This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.